The nature of placebo response in clinical studies of major depressive disorder.
Papakostas GI, Østergaard SD, Iovieno N.
J Clin Psychiatry. 2015 Apr;76(4):456-66. doi: 10.4088/JCP.14r09297.
Predictors of placebo response in bipolar depression.
Nierenberg AA, Østergaard SD, Iovieno N, Walker RS, Fava M, Papakostas GI.
Int Clin Psychopharmacol. 2015 Mar;30(2):59-66. doi: 10.1097/YIC.0000000000000058.
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Augmentation of a Nicotinic Acetylcholine Receptor Partial Agonist in Depression.
Fava M, Ramey T, Pickering E, Kinrys G, Boyer S, Altstiel L.
J Clin Psychopharmacol. 2015 Feb; 35 (1):51-56.
Updates and trends in the treatment of major depressive disorder.
Papakostas GI, Ionescu DF.
J Clin Psychiatry. 2014 Dec;75(12):1419-21. doi: 10.4088/JCP.14ac09610.
Reliability and validity of the Symptoms of Depression Questionnaire (SDQ).
Pedrelli P, Blais MA, Alpert JE, Shelton RC, Walker RS, Fava M.
CNS Spectr. 2014 Dec;19(6):535-46. doi: 10.1017/S1092852914000406. Epub 2014 Oct 2.
The implications of the National Institute of Mental Health Research Domain Criteria for researchers and clinicians.
Østergaard SD, Fava M, Rothschild AJ, Deligiannidis KM.
Acta Psychiatr Scand. 2014 Dec;130(6):409-14.
Further evidence for the reliability and validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ).
Baer L, Ball S, Sparks J, Raskin J, Dubé S, Ferguson M, Fava M.
Ann Clin Psychiatry. 2014 Nov; 26(4):270-80.
Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders.
Calabrese JR, Fava M, Garibaldi G, Grunze H, Krystal AD, Laughren T, Macfadden W, Marin R, Nierenberg AA, Tohen M.
J Affect Disord. 2014 Oct 15; 168:439-51.
How can we make measures of psychotic depression symptoms more clinically useful?
Fava M.
Acta Psychiatr Scand. 2014 Mar;129(3):161-2.
Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union.
Cooper JA, Tucker VL, Papakostas GI.
J Psychopharmacol. 2014 Feb;28(2):118-24. doi: 10.1177/0269881113514878. Epub 2013 Dec 18.
© 2024 Copyright MGH Clinical Trials Network and Institute.
Website design by Tomo360